Anti-TEM8 Antibody Development

Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a full range of monoclonal antibodies (mAbs) currently available for research of a wide variety of diseases. We guarantee generated endotoxin free antibodies are fully functional and ready to use in your antibody-based assays. In particular, Creative Biolabs now provides anti-tumor endothelial marker 8 (TEM8) antibody development services for you.

TEM8

TEM8, also known as ANTXR1, is a highly conserved 85 KDa single-pass, cell-surface trans-membrane glycoprotein originally identified on the basis of its upregulation in human tumor endothelium. The exact physiologic function of TEM8 is unknown but it is thought to play vital roles in angiogenesis, cellular adhesion, extracellular matrix homeostasis, and promotion of tumor growth. TEM8 can bind collagen types I and VI and aid in cell spreading and migration on collagen I in vitro. TEM8 was found to be broadly expressed throughout the stroma of most primary tumors and metastases in humans, such as breast, colon, lung, and pancreatic tumors. Besides, it has not been demonstrated to be present in normal tissue such as the corpus luteum, healing wounds, or normal physiologic angiogenesis. TEM8 upregulation during tumor angiogenesis, but not normal angiogenesis, suggests that TEM8 targeting may have minimal off-target toxicity.

Fig.1 Some well-characterized tumor endothelial markers. (Neri, 2005)

Antibody Therapy against TEM8

Antibodies developed against the extracellular domain of TEM8 inhibited tumor-induced angiogenesis, displayed broad anti-tumor activity, and augmented the activity of clinically approved anticancer agents without added toxicity. Thus, TEM8 targeting may allow selective inhibition of pathological angiogenesis. In preclinical studies, treatment with naked TEM8 antibodies slowed tumor growth and prolonged survival.

Additionally, widespread over-expression of TEM8 in cancers from disparate anatomical sites suggests that TEM8-ADCs (antibody-drug conjugates) may be particularly useful for the treatment of late-stage metastatic disease. For example, an anti-TEM8 ADC (named m825-MMAE) elicited potent anticancer activity through an unexpected killing mechanism. As figure 2 shown, following the capture of ADC from the circulation, tumor-associated stromal cells release active MMAE free drug, killing nearby proliferating tumor cells in a target-independent manner. In preclinical studies, ADC treatment was well tolerated and induced regression and often eradication of multiple solid tumor types, blocked metastatic growth, and prolonged overall survival. These achievements reveal a drug delivery strategy with the potential to augment therapies against multiple cancer types.

Fig.2 Illustration showing the mechanism of the ADC targeting TEM8. (Szot, 2018)

Equipped with state-of-the-art research and manufacturing facilities, Creative Biolabs is dedicated to helping our clients design and prepare highly customized antibody products. With novel technique platform and professional experiment services, we are ready to provide you with the best antibody services against TEM8 of cancer-associated fibroblasts. Please feel free to contact us for more details.

References

1. Neri, D.; Bicknell, R. Tumour vascular targeting. Nature Reviews Cancer. 2005, 5(6), 436.
2. Szot, C.; et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. The Journal of clinical investigation. 2018, 128(7).

For Research Use Only. NOT FOR CLINICAL USE.